ATE339968T1 - Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit - Google Patents
Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheitInfo
- Publication number
- ATE339968T1 ATE339968T1 AT02757930T AT02757930T ATE339968T1 AT E339968 T1 ATE339968 T1 AT E339968T1 AT 02757930 T AT02757930 T AT 02757930T AT 02757930 T AT02757930 T AT 02757930T AT E339968 T1 ATE339968 T1 AT E339968T1
- Authority
- AT
- Austria
- Prior art keywords
- autism
- syndrome
- treatment
- sensitive
- mental retardation
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 208000036626 Mental retardation Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28091501P | 2001-04-02 | 2001-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339968T1 true ATE339968T1 (de) | 2006-10-15 |
Family
ID=23075151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02757930T ATE339968T1 (de) | 2001-04-02 | 2002-04-02 | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6890931B2 (de) |
| EP (1) | EP1392363B1 (de) |
| JP (1) | JP2005500260A (de) |
| AT (1) | ATE339968T1 (de) |
| AU (1) | AU2002307049A1 (de) |
| CA (1) | CA2442478C (de) |
| DE (1) | DE60214846T2 (de) |
| ES (1) | ES2272754T3 (de) |
| WO (1) | WO2002078745A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6916821B2 (en) * | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| EP1685379A4 (de) * | 2003-07-11 | 2007-07-11 | Merck & Co Inc | Verfahren zur identifizierung von zelloberflächen-rezeptorprotein-modulatoren |
| SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
| US20080187492A1 (en) * | 2004-04-16 | 2008-08-07 | Mcbride Sean M J | Drosophila Models For Diseases Affecting Learning and Memory |
| AU2006240846B2 (en) * | 2005-04-19 | 2011-10-06 | Otsuka Pharmaceutical Factory, Inc. | Artificial cerebrospinal fluid |
| WO2007002285A2 (en) * | 2005-06-21 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Methods for treating neurological and psychiatric conditions |
| WO2007029063A2 (en) * | 2005-07-29 | 2007-03-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Treatment and/or prevention of pervasive developmental disorders |
| US7531541B2 (en) * | 2005-09-20 | 2009-05-12 | Vanderbilt University | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders |
| EP1948667B1 (de) | 2005-11-08 | 2012-04-11 | F. Hoffmann-La Roche AG | Thiazolo[4,5-c]pyridinderivative als antagonisten des mglu5-rezeptors |
| PL2083811T3 (pl) * | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| ES2446269T3 (es) * | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
| US8340770B2 (en) * | 2007-06-26 | 2012-12-25 | Durand Dominique M | Controlling seizure activity with electrical stimulation |
| WO2009047303A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder |
| US20090167322A1 (en) * | 2007-12-28 | 2009-07-02 | Erik Edmund Magnuson | Systems and method for classifying a substance |
| WO2010093859A1 (en) | 2009-02-12 | 2010-08-19 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| WO2011053636A1 (en) * | 2009-10-27 | 2011-05-05 | Mount Sinai School Of Medicine | Methods of treating psychiatric or neurological disorders with mglur antagonists |
| US20130058915A1 (en) * | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012024630A1 (en) * | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| US20130225623A1 (en) * | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| CA2885808A1 (en) * | 2012-10-23 | 2014-05-01 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of autistic disorders |
| CN106102742A (zh) * | 2013-09-13 | 2016-11-09 | 因莱塔生物科技有限责任公司 | 利用细胞外钙调节针对代谢型谷氨酸受体的药物作用 |
| CA2985301A1 (en) | 2015-06-03 | 2016-12-08 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| WO2023279193A2 (en) * | 2021-07-08 | 2023-01-12 | The Royal Institution For The Advancement Of Learning/Mcgill University | Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197820B1 (en) * | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| EP1002535A1 (de) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs |
| AU5667900A (en) | 1999-06-30 | 2001-01-22 | Prescient Neuropharma Inc. | 2-aminoindane analogs |
| EP1210338A2 (de) | 1999-08-05 | 2002-06-05 | IGT Pharma Inc. | 1,4-diazepin-derivate zur behandlung von krankheiten des zentralen nervensystems |
| KR100875222B1 (ko) * | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| US6313159B1 (en) * | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
-
2002
- 2002-04-02 ES ES02757930T patent/ES2272754T3/es not_active Expired - Lifetime
- 2002-04-02 EP EP02757930A patent/EP1392363B1/de not_active Expired - Lifetime
- 2002-04-02 US US10/114,433 patent/US6890931B2/en not_active Expired - Lifetime
- 2002-04-02 DE DE60214846T patent/DE60214846T2/de not_active Expired - Lifetime
- 2002-04-02 WO PCT/US2002/010211 patent/WO2002078745A2/en active Search and Examination
- 2002-04-02 CA CA002442478A patent/CA2442478C/en not_active Expired - Fee Related
- 2002-04-02 AT AT02757930T patent/ATE339968T1/de not_active IP Right Cessation
- 2002-04-02 AU AU2002307049A patent/AU2002307049A1/en not_active Abandoned
- 2002-04-02 JP JP2002577009A patent/JP2005500260A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002078745A3 (en) | 2002-11-28 |
| DE60214846D1 (de) | 2006-11-02 |
| EP1392363B1 (de) | 2006-09-20 |
| WO2002078745A2 (en) | 2002-10-10 |
| DE60214846T2 (de) | 2007-05-16 |
| ES2272754T3 (es) | 2007-05-01 |
| AU2002307049A1 (en) | 2002-10-15 |
| CA2442478A1 (en) | 2002-10-10 |
| EP1392363A2 (de) | 2004-03-03 |
| US6890931B2 (en) | 2005-05-10 |
| US20030100539A1 (en) | 2003-05-29 |
| CA2442478C (en) | 2010-02-02 |
| JP2005500260A (ja) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE339968T1 (de) | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
| TR200101499T1 (tr) | Azepinoindol türevleri, hazırlanmaları ve kullanımları. | |
| RS20060129A (en) | /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| ATE253063T1 (de) | 5-ht1f-agonisten | |
| GB0111186D0 (en) | Novel compounds | |
| ATE218342T1 (de) | Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| ATE223399T1 (de) | Quinazolin-4-on ampa antagonisten | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| ID25478A (id) | Agonis 5-ht1f | |
| DE60310730D1 (de) | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege | |
| ATE443060T1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
| BRPI0410026A (pt) | derivados de 3-amino-croman quinolina | |
| MXPA04001205A (es) | Compuesto para eliminar y/o mitigar la anhedonia. | |
| DE60100045D1 (de) | 1,2-Substituierte 2,3-dihydro-1H-5,9-dioxacyclohepta(f)inden-7-one und 7-substituierte Benzo(b)[1,4]dioxepin-3-one | |
| DK1055665T3 (da) | 3-(3-hydroxyphenyl)-3-aminopropionamidderivater | |
| ATE236625T1 (de) | Verwendung von 5ht2a und 5ht2a/c antagonisten zur herstellung von arzneimitteln zur behandlung des schnarchens und des herhoten widerstandes der oberen luftwege | |
| SE9901273D0 (sv) | Novel compounds | |
| ATE263139T1 (de) | 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |